SHR-1819 Injection Placebo

DRUG4 trials

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

Conditions

Adolescents With Moderate-to-severe Atopic DermatitisPrurigo NodularisSeasonal Allergic Rhinitis

Phase 2

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

RecruitingNCT06554509

Guangdong Hengrui Pharmaceutical Co., LtdPrurigo Nodularis

Start: 2024-09-19End: 2028-10-01Target: 423Updated: 2026-04-29

A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis

CompletedNCT07091357

Guangdong Hengrui Pharmaceutical Co., LtdSeasonal Allergic Rhinitis

Start: 2025-08-06End: 2025-12-01Updated: 2026-08-27

Phase 3

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

RecruitingNCT07309055

Guangdong Hengrui Pharmaceutical Co., LtdAdolescents With Moderate-to-severe Atopic Dermatitis

Start: 2026-03-21End: 2027-12-01Target: 201Updated: 2026-09-08

A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis

RecruitingNCT07688772

Guangdong Hengrui Pharmaceutical Co., LtdSeasonal Allergic Rhinitis

Start: 2026-08-11End: 2026-12-01Target: 196Updated: 2026-08-17